Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2677760 | 0.78 | MEN1 (0.31) | — | |
| SCHEMBL11291871 | 0.78 | MEN1 (0.31) | — | |
| SCHEMBL769601 | 0.73 | EGFR (0.33) | — | |
| SCHEMBL75234 | 0.73 | MEN1 (0.47) | — | |
| SCHEMBL769217 | 0.72 | — | — | |
| Ammonia Solution, Strong SCHEMBL2943006 | 0.71 | MEN1 (0.46) | — | |
| SCHEMBL1012600 | 0.69 | MEN1 (0.32) | — | |
| SCHEMBL1256324 | 0.69 | MEN1 (0.32) | — | |
| SCHEMBL9712584 | 0.69 | CNR1 (0.30) | — | |
| SCHEMBL1015719 | 0.69 | MEN1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241786-B2 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-10 | — | — | US | claimed |
| EP-1636220-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2004099200-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| US-7241786-B2 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1636220-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20040242666-A1 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004099200-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242666-A1 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | NPY1R, PARK7, IAPP | HCRTR2 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.